News | November 13, 2025
Kygevvi combines two pyrimidine nucleosides, doxecitine and doxribtimine, which act by integrating deoxycytidine and deoxythymidine into skeletal muscle mitochondrial DNA
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors
Takeda will seek an external partner to leverage its cell therapy platform technologies
Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers
Collaboration matches more eligible patients, including those with rare and complex diseases, to appropriate clinical trials
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
Late-breaking data presented at WCLC highlight significant and sustained improvements in overall survival, including more than doubling five-year survival rates compared to chemotherapy alone
Subscribe To Our Newsletter & Stay Updated
